Protocol Ledger

NCT06844383 · Phase II · RECRUITING

A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide

Interventional Phase II clinical trial protocol NCT06844383 sponsored by Prostate Cancer Clinical Trials Consortium in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-05-04 Enrollment: 126 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06844383
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)126 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06844383
Protocol FieldVerified Registry Value
NCT IdentifierNCT06844383
Consolidated Lead SponsorProstate Cancer Clinical Trials Consortium
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment126 participants (ESTIMATED)
Registered Start Date2026-05-04
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI